Eris Biotech is a biotechnology company dedicated to developing innovative cancer therapies that harness the body's immune system to combat malignancies. Recognizing that cancer cells often evade immune detection, leading to treatment failures, Eris Biotech has identified a novel pathway to counteract this immune evasion. Their flagship product is a first-in-class, orally administered small-molecule inhibitor designed to reawaken the immune response against cancer cells. This approach does not rely on targeting specific proteins, thereby broadening its applicability across a diverse patient population. Key Features and Functionality: - Oral Administration: The drug is designed for oral intake, enhancing patient convenience and compliance. - Immune System Activation: It targets a unique pathway to prevent cancer cells from evading immune detection, effectively reactivating the body's natural defenses. - Broad Applicability: By not depending on specific protein targets, the therapy is suitable for a wider range of patients and various cancer types. Primary Value and Problem Solved: Eris Biotech's solution addresses the critical challenge of immune evasion by cancer cells, a major factor in the failure of existing treatments. By reactivating the immune system through a safe and easily administered oral drug, they offer a promising alternative to traditional therapies, potentially improving outcomes for patients who have limited options.